RecruitingPhase 1NCT06999434
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Sponsor
Yale University
Enrollment
105 participants
Start Date
May 5, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Eligibility
Min Age: 18 YearsMax Age: 90 Years
Inclusion Criteria3
- Male and Female subjects must be ≥18 and \<90 years of age;
- Able to understand and provide informed consent prior to study procedures
- Must be in good health
Exclusion Criteria6
- Less than 18 years of age;
- Pregnant or breastfeeding;
- Any significant systemic illness or unstable medical condition;
- Pre-existing medical conditions or claustrophobic reactions;
- Research-related radiation exposure exceeds current PET Center guidelines (i.e. 50 mSv in the prior 12 months);
- History of a bleeding disorder or are currently taking anticoagulants.
Interventions
DRUG[11C]PIB
PET Scan #1
DRUG[ 18F]3F4AP
PET Scan #3
DRUG[18F]MK6240
PET Scan #2
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06999434
Related Trials
Evaluation of a Neuropsychological Tool to Assess Temporal Processing Abilities in Alzheimer's Disease
NCT073410091 location
Social-cognitive Functioning: Validation of a New Neuropsychological Test
NCT055587091 location
COGSCREEN II: Early Detection of Cognitive Impairment
NCT074663941 location
At Home Use of Stimulation Suits for Managing MS Symptoms
NCT072021952 locations
The Effects of Some Antihyperglycemic Drugs on Cognitive Function and Risk of Depression of Diabetic Patients
NCT072447701 location